Breast Cancer: Open Trials


ABCSG 18 ZA

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy/ Zoledronic Acid (ZA) Substudy

ABCSG 18 ZA was developed as an additional protocol to assess the effects of a single intravenous ZA administration on bone density, fracture incidence, and bone turnover markers (CTX and osteocalcin) in a subset of ABCSG 18 patients after discontinuation of denosumab.



ABCSG 22R-QoL

A questionnaire investigating long-term quality of life (QoL) outcome including sexual health and fertility concerns based survey among breast cancer patients registered in ABCSG 22R.



ABCSG 45

A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status



ABCSG 47 / IMpassion030

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

ABCSG 50/BRCA-P

A randomized, double-blind, placebo-controlled, multi-center, international phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.



ABCSG 51/ AURORA

Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer